UK secures £500m biopharma investment as Vertex commits over £300m to new Oxford R&D hub, while Teva plans New Jersey plant closure

The UK government’s autumn budget has attracted about £500 million in new biopharma commitments, signalling strong support for the sector.

Vertex Pharmaceuticals disclosed that it will put more than £300 million into a purpose‑built research and development campus in Oxford, expanding the company’s European footprint.

At the same time, Teva Pharmaceutical Industries said it will close its manufacturing facility in New Jersey, a move that will reduce its US production capacity.

The announcement also referenced other companies such as Esteve and Regeneron, though no further details were provided.